Navigation Links
Positive results from placebo-controlled phase IIa study in,patients suffering from house dust mite allergy

r /> and female patients aged 18 to 65 and suffering from mild to moderate perennial allergic rhinitis due
to house dust mite allergy. Upon entry into the study, the allergic status of the individual
participants was recorded by the conjunctival provocation test, a commonly used allergy test. The
study participants were randomized into 4 treatment groups with 10 patients each and received 6
weekly subcutaneous injections of either i) 300 ?g CYT003-QbG10 alone, ii) 300 ?g CYT003-QbG10
plus a low dose of house dust mite allergen extract (designated CYT005-AllQbG10), iii) a low dose of
house dust mite allergen extract alone, or iv) placebo. The house dust mite allergen dose
administered in treatment arms ii) and iii) was 10-times lower than that usually applied in
conventional desensitization therapy. Two weeks after the last dose, the allergic status of the
patients was again assessed by the conjunctival provocation test, which served as the primary
efficacy parameter of the study. All 40 patients were included into the analysis.

About CYT003-QbG10
CYT003-QbG10 is an immunotherapeutic product in development for the treatment of allergy, asthma
and atopic dermatitis. It consists of the ImmunodrugTM QbG10 which is comprised of the virus-like
particle Qb filled with a synthetic immunostimulatory DNA sequence called G10. CYT003-QbG10 is
designed as a disease-modifying treatment and aims to induce a potent Th1 type immune response
in order to suppress an “allergic” Th2 type immune response. An earlier, open-label phase IIa study
with CYT003-QbG10 combined with an allergen extract of house dust mites at a standard dose
showed excellent long-term efficacy in patients allergic to dust mites. Furthermore, a placebocontrolled
phase IIa study with CYT003-QbG10 showed significant improvement of allergy symptoms
in hay fever patients. CYT003-Qb
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
(Date:7/11/2014)... LONDON , July 11, 2014 ... ended at 4,396.20, down 0.52%, the Dow Jones Industrial Average ... 500 closed at 1,964.68, down 0.41%. The losses were broad ... in negative. The S&P 500 Health Care Sector Index ended ... advanced 2.75% in the last one month. Investor-Edge has initiated ...
(Date:7/11/2014)... According to a new market ... (Endoscopes, Endoscopic Operative Devices, and Visualization Systems) - Global ... the global endoscopy devices market was valued at USD ... at a CAGR of 6.8% from 2013 to 2019, ... in 2019. Browse the full Endoscopy Devices Market ...
(Date:7/11/2014)... , July 11, 2014 Research ... addition of the "Immunoprotein Diagnostic Testing Market ... the highest CAGR of 6% and is expected ... report to their offering. ... immunoprotein diagnostic testing has been segmented according to ...
Breaking Medicine Technology:Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2
... Inc. (Nasdaq: CALP ) will conduct a ... results at 9:00 a.m. ET on Thursday, October 28. ... McAree, Chief Financial Officer, will host the call. Management ... outlook for the future. A news ...
... Oct. 14 OrthoAccel Technologies, Inc., developers of ... to enhance orthodontics, announced this week that it ... its Corporate Board.  Mr. Cooper,s directorship will involve ... strategy, with a focus on market growth. ...
Cached Medicine Technology:Caliper Life Sciences' Third Quarter 2010 Financial Results Conference Call Notice 2Medical Device Industry Executive Joins OrthoAccel Technologies, Inc. Board of Directors 2Medical Device Industry Executive Joins OrthoAccel Technologies, Inc. Board of Directors 3
(Date:7/11/2014)... As reported by Forbes in the article Robert ... Blame (6/30), Indino Downey has reportedly been arrested after ... it with. His father, well-known actor Robert Downey Jr. ... him may have something to do with his addiction ... 1980s and 1990s for substance abuse before finally getting ...
(Date:7/11/2014)... Los Angeles, CA (PRWEB) July 11, 2014 ... Kevin Sands today announces that he uses mini and ... these treatments offer the defining feature that distinguishes dental ... of teeth in addition to the crowns. This alone ... dental implants also offer advantages related to comfort, ...
(Date:7/11/2014)... July 11, 2014 (HealthDay News) -- Polio is history ... places like Afghanistan, Nigeria and Pakistan. Giving vaccinated children ... their immunity and help eradicate the highly infectious disease, ... is highly effective, immunity wanes as early as a ... be infected and contribute to the spread of the ...
(Date:7/11/2014)... breast cancer patients, the era of personalized medicine may ... by USC Stem Cell researcher Min Yu and scientists ... In a July 11 study in Science , ... cancer cells circulating through the blood streams of six ... "seeds" of metastasis, which travel to and establish secondary ...
(Date:7/11/2014)... American Farmer is proud to announce their latest ... at 8:30 am ET. , In this episode, American ... designed and formulated for use on a wide range ... help the crop realize its maximum genetic yield potential ... The show also features UniSouth Genetics, a non-profit co-op ...
Breaking Medicine News(10 mins):Health News:Roberty Downey's Son Arrested For Cocaine 2Health News:Dental Implant Dentist, Kevin Sands DDS, Now Uses Mini and Full Mouth Implants to Replace Missing Teeth 2Health News:Researchers Assess New Way to Boost Polio Immunity 2Health News:New Episode of American Farmer Featuring Sunbelt, UniSouth Genetics, and Michigan Milk Producers Association Airing on RFD-TV 2
... 2008-2009 Term, FREDERICK, Md., April 8, 2008 ... and management,consulting firm, was recently elected as President of ... Association (HCAA). He,will begin his one-year term in October ... for facilitating the,transition of a new management company. Bastis ...
... April 8, 2008 CryoLife, Inc. (NYSE:,CRY) ... company,announced today that William F. Northrup, III, ... medical relations and education, reporting to Steven ... newly created position, Dr. Northrup, a board-certified,cardiovascular ...
... Work, Stability Characterization of Dry-Patch ... Vaccine ... ) today announced it will receive a,cost-reimbursement grant for up to $943,856 ... work on a,patch-based version of the anthrax vaccine., Under the 1-year ...
... employees, CHARLOTTESVILLE, Va., April 8, 2008 ... launched a,new online training module for their CareTracker ... of employees on the use of CareTracker., ... as Silverchair,s,eLearning system for senior care facilities: the ...
... will test effectiveness of health,management programs to ... in the,Medicare population, MINNEAPOLIS, April 8, ... today it is working with Pfizer Health,Solutions ... as part of a,three-year Senior Risk Reduction ...
... Commences for Issuance of Certification to Operate HMO, ... Group, Inc. (Phyhealth) (Pink Sheets: PHYH), a developer ... announced that all applications for the launch of ... been filed and accepted for review by the ...
Cached Medicine News:Health News:Brian Bastis Elected as National CPA Health Care Advisors Association Executive Committee President 2Health News:William F. Northrup, III, M.D. Joins CryoLife as Vice President of Medical Relations and Education 2Health News:William F. Northrup, III, M.D. Joins CryoLife as Vice President of Medical Relations and Education 3Health News:Iomai Wins Department of Defense Grant to Develop a Stable, Patch-Based Anthrax Vaccine 2Health News:Iomai Wins Department of Defense Grant to Develop a Stable, Patch-Based Anthrax Vaccine 3Health News:Iomai Wins Department of Defense Grant to Develop a Stable, Patch-Based Anthrax Vaccine 4Health News:Resource Systems and Silverchair Learning Systems Launch CareTracker Online Training Module 2Health News:HealthFitness Teams with Pfizer Health Solutions to Implement CMS Senior Risk Reduction Demonstration Project 2Health News:HealthFitness Teams with Pfizer Health Solutions to Implement CMS Senior Risk Reduction Demonstration Project 3Health News:HealthFitness Teams with Pfizer Health Solutions to Implement CMS Senior Risk Reduction Demonstration Project 4Health News:Phyhealth HMO Applications Accepted by All Required Federal and State Agencies 2
... Plate is a semi-rigid system intended ... The Slim-LOC is based on the ... current market technology. The Slim-LOCTM system ... instrumentation. Reduced width (16 mm), low ...
... SC-Acufix anterior cervical plate system is a ... integrated swivel, which provides for consistent, reliable ... bone screw disengagement or backout. This innovative ... locking screw. Simply implant your screws and ...
... a leading provider of telemedicine solutions. ... state-of-the-art technology deliver accurate, reliable and ... professionals and clients in improving outcomes. ... ECG technology to gather patient data, ...
... is a high performance temperature controlled shaker ... shaking speed and incubation time are fully ... parameters are displayed on the LCD in ... below the microplates provide uniform incubation with ...
Medicine Products: